The Texas Construction News staff writer
HOUSTON — Eli Lilly and Co.has announced plans to build a new $6.5 billion manufacturing facility in Houston.
The new site, located at Generation Park, will produce active pharmaceutical ingredients (APIs) for Lilly’s medicines, including treatments for cardiometabolic health and oncology. The facility will manufacture orforglipron, an oral medication under development for obesity and type 2 diabetes.
The project is expected to create 615 permanent jobs in engineering, science, and operations, in addition to construction jobs during its five-year development.
